15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Therapeutics Announces Closing of $25 Million Registered Direct Offering
October 09, 2019 10:35 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, Oct. 09, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Scilex Holding Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
September 23, 2019 07:00 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), announced that it has confidentially...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Scilex Holding Announces Strong ZTlido Sales Growth After Successful Post-Merger Integration
June 05, 2019 07:00 ET | Sorrento Therapeutics, Inc.
ZTlido® gross sales grew from approximately $1 million in March to $2.4 million in April and $3.3 million in MaySP-102 pivotal phase 3 trial remains on track for completion in H1 2020ZTlido® 5.4% (3 X...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Cannabidiol (CBD) Global Joint Ventures and Commercial Strategic Partnerships
June 04, 2019 07:00 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, June 04, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Sorrento, Nasdaq: SRNE) announces that it has formed a Chinese joint venture, Shenzhen Yunma Biotechnology Co., Ltd....